<?xml version='1.0' encoding='utf-8'?>
<document id="24023315"><sentence text="Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer."><entity charOffset="28-37" id="DDI-PubMed.24023315.s1.e0" text="topotecan" /><entity charOffset="42-51" id="DDI-PubMed.24023315.s1.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.24023315.s1.e0" e2="DDI-PubMed.24023315.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24023315.s1.e0" e2="DDI-PubMed.24023315.s1.e1" /></sentence><sentence text="Combination metronomic topotecan plus pazopanib is active against preclinical models of gynecological cancer"><entity charOffset="23-32" id="DDI-PubMed.24023315.s2.e0" text="topotecan" /></sentence><sentence text=" Both agents are substrates for ATP-binding cassette family transporters so there is an increased likelihood for pharmacokinetic (PK) drug-drug interactions" /><sentence text="" /><sentence text="PK analyses of topotecan were performed during three cycles of a phase I dose-escalation study of metronomic topotecan and pazopanib in consenting adult patients with gynecological cancer"><entity charOffset="15-24" id="DDI-PubMed.24023315.s5.e0" text="topotecan" /><entity charOffset="109-118" id="DDI-PubMed.24023315.s5.e1" text="topotecan" /><entity charOffset="123-132" id="DDI-PubMed.24023315.s5.e2" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.24023315.s5.e0" e2="DDI-PubMed.24023315.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24023315.s5.e0" e2="DDI-PubMed.24023315.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24023315.s5.e0" e2="DDI-PubMed.24023315.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24023315.s5.e1" e2="DDI-PubMed.24023315.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24023315.s5.e1" e2="DDI-PubMed.24023315.s5.e2" /></sentence><sentence text=" Concentration time data were analyzed using a population PK approach" /><sentence text="" /><sentence text="Twenty-one patients were evaluable for serial PK studies" /><sentence text=" Considerable inter- and intra-patient variability was observed in the PK parameters, attributable primarily to highly variable oral bioavailability" /><sentence text=" No difference in topotecan disposition was detected between administration cycles, nor between the off- versus on-pazopanib studies"><entity charOffset="115-124" id="DDI-PubMed.24023315.s10.e0" text="pazopanib" /></sentence><sentence text="" /><sentence text="The lack of a statistically significant drug-drug interaction agrees with preclinical findings suggesting that pazopanib does not influence the PK of metronomic topotecan"><entity charOffset="111-120" id="DDI-PubMed.24023315.s12.e0" text="pazopanib" /><entity charOffset="161-170" id="DDI-PubMed.24023315.s12.e1" text="topotecan" /><pair ddi="false" e1="DDI-PubMed.24023315.s12.e0" e2="DDI-PubMed.24023315.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24023315.s12.e0" e2="DDI-PubMed.24023315.s12.e1" /></sentence><sentence text=" No adjustment of low dose metronomic topotecan dosing is merited when used in conjunction with pazopanib"><entity charOffset="38-47" id="DDI-PubMed.24023315.s13.e0" text="topotecan" /><entity charOffset="96-105" id="DDI-PubMed.24023315.s13.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.24023315.s13.e0" e2="DDI-PubMed.24023315.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24023315.s13.e0" e2="DDI-PubMed.24023315.s13.e1" /></sentence><sentence text="" /></document>